19 Jun 2018
Cancer52, together with use MY data, has produced a briefing paper entitled National Data Opt-out and what it means to cancer patients.
The paper was produced for distribution on the Cancer52 and use MY data shared stand at the PHE Cancer Data and Outcomes Conference 2018.
1 Apr 2017
As at April 2017, Cancer52 has published a review of the progress of the recommendations contained in ‘Achieving World Class Cancer Outcomes: A Strategy for England 2015-2020’ in its Cancer Strategy recommendations grid April .
28 Jul 2016
On 28th July 2016 Cancer52 published its Cancer52 Position Paper on the new Cancer Drugs Fund Operating Model FINAL 28th July 2016.
22 Jun 2016
On 22nd June 2016 Cancer52 published its Cancer52 position statement Cancer Implementation Plan June 2016 FINAL.
23 Dec 2015
On 23rd December 2015, Cancer52 published its Briefing Paper on Access to Medicines and Treatments.
7 Dec 2015
A briefing on the implementation of Achieving World Class Outcomes: A Strategy for England 2015-2020.
5 Jun 2014
On 5th June 2014, Cancer52 published its Briefing Paper on Access to Orphan Medicines in the UK.
24 Feb 2014
On 24th February 2014, Cancer52 published its Briefing Paper on the UK Strategy for Rare Diseases.
21 Feb 2014
On 21st February 2014, Cancer52 published its Briefing Paper "VBA: NICE do it their way".
20 Sep 2013
On 20th September 2013, Cancer52 published Briefing Papers on Value Based Pricing (VBP) and the Cancer Drugs Fund (CDF); alongside an introductory debate on the topic among leading experts from within the Cancer52 family.
National Data Opt-out and what it means to cancer patients
Cancer Strategy recommendations grid April
Briefing paper on the New Cancer Drug Fund Operating Model
Briefing paper on England Cancer Strategy Implementation Plan
Briefing paper on Access to Medicines and Treatments
Policy briefing on Achieving World Class Outcomes
Briefing paper on Access to Orphan Medicines in the UK
Briefing paper on the UK Strategy for Rare Diseases: Making sure that rare cancers aren’t written out of the script
Briefing paper on NICE and Value Based Assessment (VBA)
Briefing paper on Value Based Pricing and Cancer Drugs Fund
Position statement on Value Based Pricing